

**PROTEIN CONJUGATES WITH A WATER-SOLUBLE
BIOCOMPATIBLE, BIODEGRADABLE POLYMER**

This application claims the benefit of U.S.
Provisional Application No. 60/397,509, filed July 19,
5 2002, incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Due to recent advances in genetic and cell
engineering technologies, proteins known to exhibit
10 various pharmacological actions *in vivo* are capable of
production in large amounts for pharmaceutical
applications. Examples of such proteins include
erythropoietin (EPO), granulocyte colony-stimulating
factor (G-CSF), interferons (alpha, beta, gamma,
15 consensus), tumor necrosis factor binding protein
(TNFbp), interleukin-1 receptor antagonist (IL-1ra),
brain-derived neurotrophic factor (BDNF), keratinocyte
growth factor (KGF), stem cell factor (SCF),
megakaryocyte growth differentiation factor (MGDF),
20 osteoprotegerin (OPG), interferon (IFN), consensus
interferon (CIFN), novel erythropoiesis stimulating
protein (NESP), glial cell line derived neurotrophic
factor (GDNF) soluble extracellular domain of tumor
necrosis factor receptor fused to the Fc domain of an
25 antibody (etanercept), antibodies to specific to
various different antigens, and obesity protein (OB
protein). OB protein may also be referred to herein as
leptin.

The availability of such recombinant proteins
30 has engendered advances in protein formulation and
chemical modification. One goal of chemical
modification is protein protection. Chemical
attachment may effectively block a proteolytic enzyme

from physical contact with the protein backbone itself, and thus prevent degradation. Additional advantages include, under certain circumstances, increasing the stability and circulation time of the therapeutic
5 protein, thereby increasing its therapeutic efficacy by reducing the ability of the immune system to detect and eliminate the therapeutic moiety.

There are several methods of chemical modification of useful therapeutic proteins which have
10 been reported. For example, chemical modification using water soluble polymers (including, but not limited to, polyethylene glycols, copolymers of ethylene glycol/propylene glycol, polyvinyl alcohol, carboxymethylcellulose, polyvinyl pyrrolidone, poly-1,
15 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran) has been extensively studied, and several polymer-protein conjugate formulations having improved pharmacological
20 properties, e.g., enhanced serum half-life, improved stability and solubility, and decreased immunogenicity have been reported.

U.S. Patent No. 5,824,784, discloses N-terminally monopegylated granulocyte colony
25 stimulating factor ("G-CSF") and N-terminally monopegylated consensus interferon ("N-terminally monopegylated" denoting that the protein moiety has attached to it a single polyethylene glycol moiety at the N-terminus) which demonstrate, *inter alia*,
30 increased serum half-life and improved stability.

Chemical modification with a single 20 kDa polyethylene glycol (PEG) polymer at the N-terminus of leptin results in a highly efficacious molecule which demonstrates substantial dose reduction and increased

solubility relative to the unmodified native protein;
see, e.g., PCT WO 96/40912.

Unfortunately, there are still a few
limitations associated with certain such chemical
5 modifications. For example, the use of polymers in
chronic applications and/or in relatively large
amounts, the potentially undesirable effects of the
accumulation of high molecular weight, synthetic, non-
biodegradable polymers are of concern. In addition,
10 PEG-protein conjugates have been found to accumulate in
kidney vacuoles when administered regularly over a
period of time at high doses; see e.g., Conover et al.,
Artificial Organs, 21(5):369-378 (1997); Bendele et
al., *Toxicological Sciences*, 42:152 (1997). Although
15 it is not known if such vacuoles are detrimental to the
health of an individual, it is preferable that drug
administration have no associated abnormalities.

There would thus be a clear advantage for a
biodegradable, biocompatible, water soluble polymeric
20 carrier of proteins wherein the polymeric carrier can
be metabolized or hydrolyzed and eventually eliminated
from the body. The present invention addresses this
issue and provides methods for preparing protein
conjugates with a water-soluble biodegradable,
25 biocompatible polyacetal polymer. Importantly, the
polyacetal-protein conjugates described herein were
biologically active and did not produce any undesirable
side effects (e.g., kidney vacuole formation) in
experimental animals.

30

SUMMARY OF THE INVENTION

The present invention relates to
biodegradable, biocompatible polyacetal derivatives,

and methods for making and using them. Importantly, the polyacetal derivatives can be conjugated to proteins to provide for polyacetal-protein conjugates which demonstrate advantages in bioavailability and biocompatibility compared to unconjugated proteins, without any undesirable side effects.

The present invention further relates to processes for preparing the polyacetal-protein conjugates described above. The principal embodiment of the method for making the preparation of the polyacetal-protein conjugate comprises: (a) preparing a poly-acetal derivative; (b) conjugating said polyacetal derivative to a protein to provide a polyacetal-protein conjugate; (c) isolating said polyacetal-protein conjugate. In a more specific embodiment the polyacetal is poly-(hydroxymethylene hydroxymethylformal). In another specific embodiment, the poly-(hydroxymethylene hydroxymethylformal)-protein conjugate is substantially homogenous.

The present invention further relates to all of the polyacetal-protein conjugates as above, in a pharmaceutically acceptable carrier.

The present invention also relates to methods of treatment of individuals using the polyacetal-protein conjugates as above.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph depicting single dose induced weight loss percentages for various leptin preparations in a model wherein mice were dosed with either a single subcutaneous injection of 1 mg/kg or 10 mg/kg of each preparation. Percent (%) weight loss is plotted vs. number (#) of days. Percent weight loss is

calculated as the difference between test group and buffer control.

Figure 2 is a graph depicting single dose
5 induced weight loss percentages for various leptin
preparations in a model wherein mice were dosed with
either a single subcutaneous injection of 1 mg/kg or 10
mg/kg of each preparation. Percent (%) weight loss is
plotted vs. number (#) of days. Percent weight loss is
10 calculated as the difference between test group and
buffer control.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to preparations
15 of chemically modified proteins, and methods of making
or using them. In a particular embodiment, the
invention relates to substantially homogenous
preparations of chemically modified proteins. More
specifically, the invention teaches preparations of
20 proteins conjugated to polyacetals.

U.S. Patent Nos. 5,811,510, 5,863,990, and
5,958,398 describe biodegradable, biocompatible
polyacetals, methods for their preparation, and methods
for treating and studying mammals by administration of
25 biodegradable, biocompatible polyacetals. The
biodegradable, biocompatible polyacetals are described
as distinct from naturally-occurring polysaccharides,
in that the polysaccharide ring structure is cleaved
during the synthesis of the biodegradable,
30 biocompatible polyacetals and is essentially absent
from the polymer structure.

Further, the biodegradable, biocompatible polyacetals are said to have a higher degree of biocompatibility relative to the polysaccharides from which they are derived, since they generally do not
5 contain cyclic carbohydrates-which are potentially receptor recognizable. One suitable polyacetal polymer included in the disclosures is poly-(hydroxymethylene hydroxymethylformal).

However, U.S. Patent Nos. 5,811,510,
10 5,863,990, and 5,958,398 do not teach conjugating biodegradable, biocompatible polyacetals to proteins as used herein, with the expectation of improving bioavailability, bioactivity and reducing or
eliminating kidney vacuole formation upon injection of
15 these conjugates in patients.

As described herein, the conjugation of proteins to biodegradable, biocompatible polyacetals can occur by using a variety of functional derivatives of biodegradable, biocompatible polyacetals which react
20 with functional groups available on the proteins for their modification. Such reactions can result in the conjugation of the protein to a polyacetal amide, amino, urethane, imino, ester, thioether or any other chemical linkage known in the art.

As used herein, the term "chemically modified protein" of the invention is understood to be a biodegradable, biocompatible polyacetal, e.g., a poly-(hydroxymethylene hydroxymethylformal), conjugated protein of the invention, wherein the biodegradable,
25 biocompatible polyacetal has been derivatized such that it has a functional side group capable of reacting with a corresponding functional group on a protein.
30

The term "protein", as used herein, is understood to include peptides, polypeptides, consensus

molecules, fusion proteins, purified naturally occurring proteins, artificially synthesized proteins, analogs, derivatives or combinations thereof.

"Substantially homogenous" as used herein
5 means that the only chemically modified proteins
observed are those having one biodegradable,
biocompatible polyacetal "modifier" (e.g., poly-
(hydroxymethylene hydroxymethylformal)) moiety. The
preparation may contain unreacted (i.e., lacking a
10 modifier moiety) protein. As ascertained by peptide
mapping and N-terminal sequencing, one example below
provides for a preparation which is at least 90%
chemically modified protein, and at most 10% unmodified
protein. Preferably, the chemically modified material
15 is at least 95% of the preparation and most preferably,
the chemically modified material is 99% of the
preparation or more.

The chemically modified material has
biological activity. The present substantially
20 homogenous biodegradable, biocompatible polyacetal-
protein preparations provided herein are those which
are homogenous enough to display the advantages of a
homogenous preparation, e.g., ease in clinical
application in predictability of lot to lot
25 pharmacokinetics.

As used herein, biologically active agents
refers to proteins, whether human or animal, useful for
prophylactic, therapeutic or diagnostic application.
These proteins have activity such as specific binding
30 to a receptor, ligand or epitope. The biological
activity is not enzymatic.

The biologically active protein can be
natural, synthetic, semi-synthetic or a derivative
thereof. A wide range of biologically active agents

are contemplated. These include but are not limited to antibodies, fusion proteins, peptides, peptibodies, hormones, cytokines, hematopoietic factors, growth factors, antiobesity factors, trophic factors, and
5 anti-inflammatory factors (see also U.S. Patent No. 4,695,463 for additional examples of useful biologically active agents). One skilled in the art will readily be able to adapt a desired biologically active agent to the compositions of present invention.

10 Such proteins would include but are not limited to interferons (see, U.S. Patent Nos. 5,372,808, 5,541,293 4,897,471, and 4,695,623 hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby
15 incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698 5,547,933, and 5,621,080 hereby incorporated by reference including drawings), granulocyte-colony stimulating factors (see, U.S.
20 Patent Nos. 4,810,643, 4,999,291, 5,581,476, 5,582,823, and PCT Publication No. 94/17185, hereby incorporated by reference including drawings), stem cell factor (PCT Publication Nos. 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings),
25 osteoprotegerin (PCT Publication No. 97/23614, hereby incorporated by reference including drawings) and leptin (OB protein).

 The type of leptin used for the present polyacetal-leptin (namely, poly-(hydroxymethylene
30 hydroxymethylformal)-leptin) preparations may be selected from those described in PCT International Publication Number WO 96/05309, as cited above and herein incorporated by reference in its entirety. Figure 3 of that publication depicts the full deduced

A-822

amino acid sequence derived for human leptin (referred to as the human "OB" protein). The amino acids are numbered from 1 to 167. A signal sequence cleavage site is located after amino acid 21 (Ala) so that the mature protein extends from amino acid 22 (Val) to amino acid 167 (Cys). For the present disclosure, a different numbering is used herein, where the amino acid position 1 is the valine residue which is at the beginning of the mature protein. The amino acid sequence for mature, recombinant methionyl human leptin is presented herein as SEQ ID NO: 1, where the first amino acid of the mature protein is valine (at position 1) and a methionyl residue is located at position -1 (not included in the sequence below).

15

SEQ ID NO: 1

 V P I Q K V Q D D T K T L I K T I V
.T R I N D I S H T Q S V S S K Q K V T G
.L D F I P G L H P I L T L S K M D Q T L
20 .A V Y Q Q I L T S M P S R N V I Q I S N
.D L E N L R D L L H V L A F S K S C H L
P W A S G L E T L D S L G G V L E A S G
.Y S T E V V A L S R L Q G S L Q D M L W
Q L D L S P G C

25

However, as with any of the present leptin moieties, the methionyl residue at position -1 may be absent.

Alternatively, one may use a natural variant of human leptin, which has 145 amino acids and, as compared to rmetHu-leptin of SEQ ID NO: 1, has a glutamine absent at position 28.

Generally, the leptin moiety for human pharmaceutical use herein will be capable of therapeutic use in humans (see also, animal leptins, below). Thus, one may empirically test activity to

determine which leptin moieties may be used. As set forth in WO 96/05309, leptin protein in its native form, or fragments (such as enzyme cleavage products) or other truncated forms and analogs may all retain biological activity. Any of such forms may be used as a leptin moiety for the present the polyacetal-leptin conjugates, although such altered forms should be tested to determine desired characteristics. See also, PCT International Publication Numbers WO 96/40912, WO 97/06816, 97/18833, WO 97/38014, WO 98/08512 and WO 98/28427, herein incorporated by reference in their entireties.

One may prepare an analog of recombinant human leptin by altering amino acid residues in the recombinant human sequence, such as substituting the amino acids which diverge from the murine sequence. Murine leptin is substantially homologous to human leptin, particularly as a mature protein and, further, particularly at the N-terminus. Because the recombinant human protein has biological activity in mice, such an analog would likely be active in humans. For example, in the amino acid sequence of native human leptin as presented in SEQ ID NO: 1, one may substitute with another amino acid one or more of the amino acids at positions 32, 35, 50, 64, 68, 71, 74, 77, 89, 97, 100, 101, 105, 106, 107, 108, 111, 118, 136, 138, 142 and 145. One may select the amino acid at the corresponding position of the murine protein (see Zhang et al., 1994, *supra*) or another amino acid.

One may further prepare "consensus" molecules based on the rat OB protein sequence. Murakami et al., *Biochem. Biophys. Res. Comm.*, 209:944-52 (1995) herein incorporated by reference. Rat OB protein differs from human OB protein at the following positions (using the

numbering of SEQ ID NO: 1): 4, 32, 33, 35, 50, 68, 71,
74, 77, 78, 89, 97, 100, 101, 102, 105, 106, 107, 108,
111, 118, 136, 138 and 145. One may substitute with
5 these divergent positions. The positions underlined
are those in which the murine OB protein as well as the
rat OB protein are divergent from the human OB protein
and, thus, are particularly suitable for alteration.
At one or more of the positions, one may substitute an
10 amino acid from the corresponding rat OB protein, or
another amino acid.

Other analogs may be prepared by deleting a
part of the protein amino acid sequence. For example,
the mature protein lacks a leader sequence (-22 to -1).
15 One may prepare the following truncated forms of human
OB protein molecules (using the numbering of
SEQ ID NO: 1):

- (i) amino acids 98-146;
- (ii) amino acids 1-99 and (connected to)
20 112-146;
- (iii) amino acids 1-99 and (connected to)
112-146 having one or more of amino acids 100-111
sequentially placed between amino acids 99 and 112.

In addition, the truncated forms may also
25 have altered one or more of the amino acids which are
divergent (in the murine, rat or rhesus OB protein)
from human OB protein. Furthermore, any alterations
may be in the form of altered amino acids, such as
peptidomimetics or D-amino acids.

30 Also included are those proteins as set forth
above with amino acid substitutions which are
"conservative" according to acidity, charge,
hydrophobicity, polarity, size or any other

characteristic known to those skilled in the art. These are set forth in Table 1, below. See generally, Creighton, *Proteins, passim* (W.H. Freeman and Company, N.Y., 1984); Ford et al., *Protein Expression and Purification* 2:95-107 (1991), which are herein
 5 incorporated by reference.

Table 1
Conservative Amino Acid Substitutions

Basic:	arginine lysine histidine
Acidic:	glutamic acid aspartic acid
Polar:	glutamine asparagine
Hydrophobic:	leucine isoleucine valine
Aromatic:	phenylalanine tryptophan tyrosine
Small:	glycine alanine serine threonine methionine

Interleukin-1 receptor antagonist (IL-1ra) is a human protein that acts as a natural inhibitor of interleukin-1. Preferred receptor antagonists, as well as methods of making and using thereof, are described in U.S. Patent No. 5,075,222 (referred to herein as the '222 patent); WO 91/08285; WO 91/17184; AU 9173636; WO 92/16221; WO93/21946; WO 94/06457; WO 94/21275; FR 2706772; WO 94/21235; DE 4219626, WO 94/20517; and WO 96/22793, the disclosures of which are incorporated herein by reference. The proteins include glycosylated as well as non-glycosylated IL-1 receptor antagonists.

Specifically, three useful forms of IL-1ra and variants thereof are disclosed and described in the '222 patent. The first of these, IL-1ra α , is characterized as a 22-23 kD molecule on SDS-PAGE with an approximate isoelectric point of 4.8, eluting from a Mono Q FPLC column at around 52 mM NaCl in Tris buffer, pH 7.6. The second, IL-1ra β , is characterized as a 22-23 kD protein, eluting from a Mono Q column at 48 mM NaCl. Both IL-1ra α and IL-1ra β are glycosylated. The third, IL-1rax, is characterized as a 20 kD protein, eluting from a Mono Q column at 48 mM NaCl, and is non-glycosylated. All three of these inhibitors possess similar functional and immunological activities.

IL-1ra was produced in *E. coli* using methods such as those described in e.g., U.S. Patent No. 5,075,222. One disclosed method consists of isolating the IL-1ra from human monocytes, where they are naturally produced. A second disclosed method involves isolating the gene responsible for coding IL-1ra, cloning the gene in suitable vectors and cells types, expressing the gene to produce the inhibitors and harvesting the inhibitors. The latter method, which is

exemplary of recombinant DNA methods in general, is a preferred method. Recombinant DNA methods are preferred in part because they are capable of achieving comparatively greater amounts of protein at greater
5 purity. Thus, the invention also encompasses IL-1ra containing an N-terminal methionyl group as a consequence of expression in prokaryotic cells, such as *E. coli*.

In addition, biologically active agents can
10 also include but are not limited to antibodies of any isotype. Specific examples include commercially available antibodies such as muromonab-CD3 (Orthoclone OKT-3™, Ortho Biotech), abciximab (ReoPro™, Lilly), rituximab (Rituxan™, IDEC), dacliximab (Zenapax™, Roche
15 Laboratories), basiliximab (Simulect™, Novartis), infliximab (Remicade™, Centocor), palivizumab (Synagis™, MedImmune), trastuzumab (Herceptin™, Genentech), gemtuzuman ozogamicin (Mylotarg™, Wyeth), and alemtuzumab (Campath™, Berlex). Further Examples
20 of antibodies or antibody/cytotoxin or antibody/luminophore conjugates contemplated for conjugation to the polymers of the invention include those antibodies that recognize one or more of the following antigens: CD2, CD3, CD4, CD8, CD11a, CD14,
25 CD18, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD147, IL-4, IL-5, IL-8, IL-10, IL-2 receptor, IL-4 receptor, IL-6 receptor, IL-13 receptor, PDGF-β, VEGF, TGF, TGF-β2, TGF-β1, EGF receptor, VEGF receptor, C5 complement, IgE, tumor
30 antigen CA125, tumor antigen MUC1, PEM antigen, LCG (which is a gene product that is expressed in association with lung cancer), HER-2, a tumor-associated glycoprotein TAG-72, the SK-1 antigen, tumor-associated epitopes that are present in elevated
35 levels in the sera of patients with colon and/or

pancreatic cancer, cancer-associated epitopes or polypeptides expressed on breast, colon, squamous cell, prostate, pancreatic, lung, and/or kidney cancer cells and/or on melanoma, glioma, or neuroblastoma cells,

5 TRAIL receptors 1, 2, 3 and 4, the necrotic core of a tumor, integrin alpha 4 beta 7, the integrin VLA-4, B2 integrins, TNF-a, the adhesion molecule VAP-1, epithelial cell adhesion molecule (EpCAM), intercellular adhesion molecule-3 (ICAM-3),

10 leukointegrin adhesin, the platelet glycoprotein gp IIb/IIIa, cardiac myosin heavy chain, parathyroid hormone, rNAPc2 (which is an inhibitor of factor VIIa-tissue factor), MHC I, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), tumor necrosis factor (TNF),

15 CTLA-4 (which is a cytotoxic T lymphocyte-associated antigen), Fc-γ-1 receptor, HLA-DR 10 beta, HLA-DR antigen, L-selectin, IFN-γ, Respiratory Syncytial Virus, human immunodeficiency virus (HIV), hepatitis B virus (HBV), *Streptococcus mutans*, and *Staphylococcus*

20 *aureus*.

Additional biologically active agents include fusion proteins such as the soluble extracellular domain of the tumor necrosis factor receptor (TNFR) fused to the Fc domain of an immunoglobulin

25 (etanercept), insulin, gastrin, prolactin, adrenocorticotrophic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), motilin, interferons (alpha, beta, gamma), tumor

30 necrosis factor (TNF), tumor necrosis factor-binding protein (TNF-bp), brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factors (FGF), neurotrophic growth factor (NGF), bone growth

35 factors such as osteoprotegerin (OPG), insulin-like

growth factors (IGFs), macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), megakaryocyte derived growth factor (MGDF), keratinocyte growth factor (KGF),
5 thrombopoietin, platelet-derived growth factor (PDGF), colony stimulating growth factors (CSFs), bone morphogenetic protein (BMP), superoxide dismutase (SOD), tissue plasminogen activator (TPA), urokinase, streptokinase, kallikrein, flt3 ligand, CD40 ligand,
10 thrombopoietin, calcitonin, Fas ligand, ligand for receptor activator of NF-kappa B (RANKL), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), thymic stroma-derived lymphopoietin, mast cell growth factor, stem cell growth factor, epidermal
15 growth factor, RANTES, growth hormone, insulinotropin, parathyroid hormone, glucagon, interleukins 1 through 18, colony stimulating factors, lymphotoxin-beta, leukemia inhibitory factor, oncostatin-M, Eph or Ephrin molecules that include the various ligands for cell
20 surface molecules ELK and Hek (such as the ligands for eph-related kinases, also known as the LERKS).

The water-soluble, biocompatible polymers contemplated for use are those described in U.S. Patent Nos. 5,811,510, 5,863,990, and 5,958,398 and the
25 methods of making said polymers are incorporated herein by reference. The biodegradable, biocompatible polyacetals are described as distinct from naturally-occurring polysaccharides, in that the polysaccharide ring structure is cleaved during the synthesis of the
30 biodegradable, biocompatible polyacetals and is essentially absent from the polymer structure. Further, the biodegradable, biocompatible polyacetals are said to have a higher degree of biocompatibility relative to the polysaccharides from which they are
35 derived, since they generally do not contain cyclic

carbohydrates-which are potentially receptor recognizable. A preferred biodegradable, biocompatible polyacetal polymer contemplated for use herein is poly-(hydroxymethylene hydroxymethylformal), or PHF.

5 Polymers of this invention are used in an activated form, *i.e.*, polymer molecules comprise functional groups suitable for conjugation with a protein. Such groups can be introduced using any strategy known in the art, for example, via a chemical
10 reaction between the polymer and a bifunctional reagent comprising said functional group, or its precursor, and a second functional group suitable for conjugation with the polymer.

 The preferred protein-binding functional
15 groups of this invention include groups capable of binding functional groups present in the protein structure. Since protein binding through amino groups and thiol groups in aqueous media is often preferable, the preferred protein binding functional groups of this
20 invention are groups capable of binding either amino groups or mercapto groups in aqueous media or in polar solvents, or mixtures thereof. Such groups are generally known in organic and bioconjugate chemistry. Examples of such groups are maleimido groups,
25 pyridyldithio groups, and N-hydroxysuccinimide ester groups.

 The preferred second functional group of this invention is a carboxyl group, which is, preferably, activated either in situ or in advance. Activation is
30 performed via formation of a carboxyl group derivative suitable for condensation with functional groups present in the polymer structure, such as, primary or secondary hydroxyls. Such derivatives are formed using reagents and methods generally known in organic and

bioconjugate chemistry. The preferred derivatives are esters and O-acylisoureas, including, but not limited to, nitrophenyl ester, N-hydroxysuccinimide ester, tetrafluorophenyl ester; N,N'-dicyclohexyl-O-acylisourea, N,N'-diisopropyl-O-acylisourea, N-(3-dimethylaminopropyl)-N'-ethyl-O-acylisourea, 1-cyclohexyl-3-(2-morpholinoethyl)-O-acylisourea.

Preparation of an activated polymer with said bifunctional reagent is preferably performed in a suitable non-aqueous media, *i.e.*, a solvent or a solvent mixture in which the polymer and all reagents are sufficiently soluble, and where none of the component adversely interferes with any of the reagents or with any processes constituting the reaction of conjugation. Examples of such media include, but are not limited to, pyridine (Py), dimethylformamide (DMF), dimethylsulfoxide (DMS), methanol, and mixtures thereof. The polymer, the bifunctional reagent, and, where necessary, one or more coupling reagents and catalysts, are combined in such media and allowed to react for a sufficient amount of time. The process can be further optimized by adjustments in the reagent concentration and composition, acidity, temperature, and other parameters. The reaction media is preferably isolated from ambient air, in particular to avoid interactions of any reagent with oxygen or water. To achieve such isolation, the reaction can be conducted in a vessel filled with dry argon or nitrogen.

In one of the preferred embodiments, the bifunctional reagent is a cyclic anhydride of a dicarbonyl acid, for example, succinic anhydride. The reaction of succinic anhydride, with PHF, preferably under argon and in the presence of a catalyst, results in the succinylated PHF, *i.e.*, a polymer comprising

succinic acid bound to the polymer via one of the carboxyls, while another carboxyl remains available for further modification. The latter carboxyl can be further activated to form an active ester or an O-acylisourea; the resultant activated polymer can be further purified, isolated, and reacted with a protein to form a conjugate. Alternatively, the succinilated polymer can be purified and reacted with a protein in the presence of a suitable coupling reagent, such as a carbodiimide. The carboxyl group and its activated derivatives is generally known to bind proteins through amino groups of lysine, terminal amino groups, and, at least in some instances, through histidine, tyrosine, and other amino acids.

In another preferred embodiment, the bifunctional reagent is a maleimidocarboxylic acid, for example, maleimidopropionic acid, or an activated derivative thereof, for example, an activated ester, an anhydride, a halogenanhydride, or an O-acylisourea. The reaction of maleimidocarboxylic acid with PHF, preferably under argon and in the presence of a catalyst, results in the polymer comprising maleimide groups suitable for conjugation with proteins. Such polymers is further purified, isolated, and reacted with a protein to form a conjugate. The maleimido group is generally known to bind proteins through mercaptogroups of cysteine.

Alternatively, a functional group suitable for conjugation with proteins can be introduced into the polymer structure during polymer synthesis. For example, lateral cleavage of Dextran B-512 can be performed at periodate:glucose monomer ratio of less than 2:1 mol/mol, preferably between 1.95:1 to 1.5:1, which results in ring opening without complete cleavage

of carbon 3 in some carbohydrate units. Borohydride reduction results in vicinol glycol formation in such units, which can be confirmed by proton NMR and reaction with periodate.

5 Proteins modified using one of the above approaches can be further fractionated and purified to obtain a conjugate preparation with a desired size distribution, protein content, charge, or other parameter.

10 The biological properties of protein conjugates are generally known to depend on several parameters. Although it is not bound by theory, in some particular instances, the size (molecular weight) and size distribution of polymer molecules may be of
15 particular importance. Although it is conceivable that this invention can use polymers within molecular weights as low as 1 kDa or lower, or as high as 500 kDa or higher, the preferred molecular weight range of this invention is 5 kDa to 300 kDa, most preferable 20 kDa
20 to 150 kDa.

 The invention also contemplates pharmaceutical compositions comprising effective amounts of a selected biodegradable, biocompatible polyacetal conjugated protein, or derivative products,
25 together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers needed for administration. (See PCT 97/01331 hereby incorporated by reference.) The optimal pharmaceutical formulation for a desired
30 biologically active agent will be determined by one skilled in the art depending upon the route of administration and desired dosage.

 Exemplary pharmaceutical compositions are disclosed in Remington's Pharmaceutical Sciences (Mack

Publishing Co., 18th Ed., Easton, PA, pgs. 1435-1712 (1990)). The pharmaceutical compositions of the present invention may be administered by oral and non-oral preparations (e.g., intramuscular, subcutaneous, 5 transdermal, visceral, IV (intravenous), IP (intraperitoneal), intraarticular, placement in the ear, ICV (intracerebralventricular), IP (intraperitoneal), intraarterial, intrathecal, intracapsular, intraorbital, injectable, pulmonary, 10 nasal, rectal, and uterine-transmucosal preparations).

Therapeutic uses of the compositions of the present invention depend on the biologically active agent used. One skilled in the art will readily be able to adapt a desired biologically active agent to 15 the present invention for its intended therapeutic uses. Therapeutic uses for such agents are set forth in greater detail in the following publications hereby incorporated by reference including drawings. Therapeutic uses include but are not limited to uses 20 for proteins like interferons (see, U.S. Patent Nos. 5,372,808, 5,541,293, hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 25 4,703,008, 5,441,868, 5,618,698 5,547,933, and 5,621,080 hereby incorporated by reference including drawings), granulocyte-colony stimulating factors (see, U.S. Patent Nos. 4,999,291, 5,581,476, 5,582,823, 4,810,643 and PCT Publication No. 94/17185, hereby 30 incorporated by reference including drawings), stem cell factor (PCT Publication Nos. 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings), and the OB protein (see PCT publication Nos. 96/40912, 96/05309, 97/00128, 35 97/01010 and 97/06816 hereby incorporated by reference

including figures). In addition, the present compositions may also be used for manufacture of one or more medicaments for treatment or amelioration of the conditions the biologically active agent is intended to
5 treat.

One skilled in the art will be able to ascertain effective dosages by administration and observing the desired therapeutic effect. Preferably, the formulation of the conjugate will be such that
10 between about 0.01 μ g leptin moiety/kg body weight/day and 10 mg leptin moiety/kg body weight/day will yield the desired therapeutic effect. The effective dosages may be determined using diagnostic tools over time. For example, a diagnostic for measuring the amount of
15 leptin in the blood (or plasma or serum) may first be used to determine endogenous levels of leptin protein. Such diagnostic tool may be in the form of an antibody assay, such as an antibody sandwich assay. The amount of endogenous leptin protein is quantified initially,
20 and a baseline is determined. The therapeutic dosages are determined as the quantification of endogenous and exogenous leptin protein moiety (that is, protein, analog or derivative found within the body, either self-produced or administered) is continued over the
25 course of therapy. The dosages may therefore vary over the course of therapy, with, for example, a relatively high dosage being used initially, until therapeutic benefit is seen, and lower dosages used to maintain the therapeutic benefits.

30 Therapeutic uses of polyacetal-leptin include weight modulation, the treatment or prevention of diabetes, blood lipid reduction (and treatment of related conditions), increasing lean body mass and increasing insulin sensitivity. Particular embodiments

contemplate the use of poly-(hydroxymethylene hydroxymethylformal)-leptin conjugates.

Therapeutic uses of polyacetal-IL-1ra include those described in e.g., U.S. Patent No. 5,075,222.

- 5 Particular embodiments contemplate the use of poly-(hydroxymethylene hydroxymethylformal)-IL-1ra in the therapeutic uses contemplated above.

- 10 In addition, the present compositions may be used for manufacture of one or more medicaments for treatment or amelioration of the above conditions.

The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.

15 EXAMPLE 1

- The water-soluble, biodegradable, biocompatible polymers, the 'polyacetals', contemplated for use in making conjugates of the present invention are those described in U.S. Patent Nos. 5,811,510, 20 5,863,990, and 5,958,398. This example describes the synthesis of various biodegradable, biocompatible polyacetal derivatives, namely poly-(hydroxymethylene hydroxymethylformal) aldehyde and poly-(hydroxymethylene hydroxymethylformal) maleimide.

- 25 Synthesis of Fleximer1 (Maleimido-PHF1): PHF was prepared via exhaustive lateral cleavage of dextran B-512 by periodate oxidation. Dextran of Mn 20,000 Da (15 g) was dissolved in 30 mL of deionized water. Dextran solution was treated with 50 g of sodium 30 metaperiodate dissolved in 1 L of deionized water on ice bath in a light protected reactor. The reaction mixture was incubated at 5°C for 3 hours, and then at 25°C for 10 hours. The reaction mixture was then

filtered, desalted by flow dialysis, and treated with sodium borohydride (8 g) dissolved in 50 mL of deionized water at 0°C. After a 2 hour incubation, the pH was adjusted to 6.5 with 5 N HCl. The product was
5 desalted and concentrated by flow dialysis using hollow fiber cartridge, cutoff 30 kDa. Then, the product was purified by gel chromatography on Sephadex G-25, using deionized water as an eluent. The polymer was recovered from the aqueous solutions by lyophilization;
10 yield: 60%. Size exclusion chromatography showed the same elution profile as of the original dextran B-512; ¹³C and ¹H NMR spectra were in agreement with the expected acyclic polyacetal structure.

Dry polymer, 10 g, and maleimidopropionic
15 acid, 0.5 g, were dissolved in 100 ml pyridine. The reaction mixture was placed under argon. Then, 0.67 g of N,N'-dicyclohexyl carbodiimide and 0.1 g of dimethylaminopyridine were added, and the reaction mixture was incubated for 12 hours at 25°C, filtered
20 and dried in vacuum. Then, the product was reconstituted in 100 ml cold deionized water and desalted on Sephadex G-25. Then 1 g NaCl were added to the polymer solution, and the solution was lyophilized.

Synthesis of Fleximer2: Synthesis was performed
25 analogously, using dextran 512 with molecular weight of 180 kDa, and without NaCl addition at the last (lyophilization) step.

Synthesis of FleximerG20: PHF-glycol was prepared by controlled lateral cleavage of dextran B-512 at
30 periodate:polymer molar ratio of 1.7:1, in order to obtain a polymer comprising vicinal diol groups. The polymer was prepared as described above for PHF. SEC analysis has shown no substantial difference between MW/MWD of the starting dextran B-512 and the resultant

PHF-glycol. Vicinal glycol group content, as determined by consumption of periodate was $29 \pm 3\%$ (mol/mol monomer). The polymer was lyophilized from deionized water.

- 5 Synthesis of FleximerG50: PHF-glycol with $25 \pm 2\%$ glycol content was prepared as above, using dextran B-512 with molecular weight of 70 kDa. SEC analysis has shown no substantial difference between MW/MWD of the starting dextran B-512 and the resultant PHF-glycol. The
10 polymer was lyophilized from deionized water.

EXAMPLE 2

- This example describes the synthesis of various Fleximer1-leptin and Fleximer2-leptin
15 conjugates. A recombinant methionyl human leptin analog, ^{78}C -leptin, prepared as described in the Materials and Methods section below, was used for the conjugations.

Synthesis of Fleximer1-Leptin Conjugates

- 20 Preparation 1. 40.0 mg ($2.48 \mu\text{mol}$) of ^{78}C -leptin (8.0 mL of a 5 mg/mL solution in 10 mM acetate pH 4) was diluted with 12 mL of maleimide buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA) and the pH raised to 6.5 with NaOH. A solution of 40.0 mg ($2.22 \mu\text{mol}$) of
25 Fleximer1 in 2.0 mL of maleimide buffer was added to the ^{78}C -leptin solution and stirred in the cold room for 5 days.

- The reaction mixture was then diluted with 23 mL of pH 3 water, the pH lowered to 3.5 with HCl and
30 the mixture filtered through a $0.45 \mu\text{m}$ CA filter. The filtrate was loaded onto an SP16 FPLC column in 20 mM NaOAc pH 4 and eluted with a 0.5M NaCl gradient.

A-822

Fractions 30-52 (184 mL) were combined, treated with 18.4 mL of 10X D-PBS and the pH raised to 7.0 with 1N NaOH. The combined fractions were placed in a 400 mL stirred cell with a YM-3 membrane, diluted to 350 mL with D-PBS and then concentrated to 35 mL (0.1471 mg/mL = 5.1 mg protein), then further concentrated to 20 mL.

Preparation 2: 40.0 mg (2.48 μ mol) of 78 C-leptin (8.0 mL of a 5 mg/mL solution in 10 mM acetate pH 4) was diluted with 12 mL of maleimide buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA) and the pH raised to 6.5 with NaOH. A solution of 200.0 mg (11.1 μ mol) of Fleximer1 in 2.0 mL of maleimide buffer was added to the 78 C-leptin solution and stirred in the cold room for overnight.

The reaction mixture was diluted with 23 mL of pH 3 water, the pH lowered to 3.5 with HCl and filtered through a 0.45 μ m CA filter. The filtrate was loaded onto an SP16 FPLC column in 20 mM NaOAc pH 4 and eluted with a 0.5M NaCl gradient. Fractions 25-45 (0.0750 mg/mL = 15.8 mg protein) were combined, treated with 21.0 mL of 10X D-PBS and the pH raised to 7.0 with 1N NaOH.

The products from Preparation 1 (20 mL) and Preparation 2 (210 mL) were combined and placed in a 200 mL stirred cell with a YM-3 membrane and concentrated to ~20 mL. This material was diluted with 150 mL of D-PBS and concentrated to near dryness. 5.0 mL of D-PBS were added to the cell to give 4.5 mL (4.07 mg/mL = 18.3 mg protein) of product. This solution was diluted to 2.0 mg/mL with D-PBS, sterile filtered, vialled and submitted for *in vivo* testing.

Synthesis of Fleximer2-Leptin Conjugates

40.0 mg (2.48 μ mol) of ^{78}C -leptin (8.0 mL of a 5 mg/mL solution in 10 mM acetate pH 4) was diluted with 12 mL of maleimide buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA) and the pH raised to 6.5 with NaOH. A solution of 137.5 mg (1.24 μ mol) of Fleximer2 in 3.0 mL of maleimide buffer was added to the ^{78}C -leptin solution and stirred in the cold room for 8 days.

The reaction mixture was diluted with 25 mL of D-PBS and filtered through a coarse sintered glass funnel. The filtrate was placed in a 200 mL Amicon stirred cell with a YM-100 membrane and diafiltered vs. D-PBS. A total of 485 mL of diafiltrate was collected. The retentate was concentrated to 10.7 mL (2.72 mg/mL = 29.1 mg protein). This solution was diluted to 2.0 mg/mL with D-PBS, filtered (0.45 μ m), vialled and submitted for *in vivo* testing.

EXAMPLE 3

The *in vivo* efficacy of the Fleximer1-leptin conjugate and Fleximer2-leptin conjugate was tested in wild-type mice by monitoring weight loss relative to a buffer control. The Fleximer1-leptin preparation was tested vs. a 20 kDa monoPEG-leptin preparation and each preparation was administered at 1 mg/kg/single dose, 10 mg/kg/single dose, 1 mg/kg/daily for 7 days, and 10 mg/kg/daily for 7 days. The Fleximer2-leptin preparation (at 10 mg/kg/single dose, 1 mg/kg/daily for 7 days, and 10 mg/kg/daily for 7 days) was tested vs. an Fc-leptin preparation (10 mg/kg/single dose).

As depicted in Figure 1, the Fleximer1-leptin preparation induced 12%-17% weight loss by day 7 when

administered at 10 mg/kg. The 20 kDa monoPEG-leptin preparation was also effective in inducing weight loss in the model.

As depicted in Figure 2, the Fleximer2-leptin preparation induced 14% weight loss by day 7 when administered at 10 mg/kg/daily for 7 days. The Fc-leptin preparation was also effective to some extent in inducing weight loss in the model.

10 EXAMPLE 4

The accumulation of renal vacuoles in the proximal microtubule epithelium has been observed with administration of 20 kDa mono PEGylated-leptin and is dose dependent. Although the doses required to induce vacuoles are well in excess of the therapeutic dose and even severe vacuole induction caused no detectable renal dysfunction, this apparent toxicity is considered undesirable.

In this study, adult (8-12 week-old) female C57BL/6 mice weighing 18-21g received subcutaneous injections (constant volume of 100 µl) of either buffer (PBS), 20 kDa monoPEG-leptin, Fleximer1-leptin or Fleximer2-leptin. Animals (n=5/group) were dosed according to Table 2:

25 Table 2

Group	Leptin	Daily Dose	Number of
No.	Conjugate	(mg/kg)	Days
1	PBS (neg control)	0	7
2	20k mono-PEG leptin	10	7
30 3	Fleximer1-leptin	10	7
4	Fleximer2-leptin	10	7
5	Fleximer2-leptin	1	7
6	Fleximer2-leptin	10	1
7	Fc-leptin	10	1

The dose was based on mg/kg of protein. Necropsy was performed the day of the last injection, during which spleens and kidneys (n=3/group per organ) were examined for gross abnormalities and then immersed in zinc formalin. Fixed organs were dehydrated in graded alcohols, cleared in Propar, and embedded in paraffin. Both tissues for three mice from each group were processed together. Six- μ m-thick sections were stained with hematoxylin and eosin (HE), and multiple fields were examined at 40x, 10x and 400x magnifications. The severity of vacuolar change in renal tubular epithelia and splenic macrophages was graded semi-quantitatively using a five-tiered scale: none, 1+ = minimal (rare, small vacuoles), 2+ = mild (modest numbers of ~ 3 μ m diameter vacuoles), 3+ = moderate (large numbers of ~ 3 μ m to ~ 5 μ m diameter vacuoles), or 4+ = marked (> 5 μ m in diameter vacuoles). Assessments were conducted using a "blinded" paradigm and the results of the study are depicted in Table 3.

Table 3

	Group	Leptin	Daily Dose	# of	Kidney	Spleen
25	No.	Conjugate	(mg/kg)	Days	Score	Score
	1	PBS (neg control)	0	7	None	None
	2	20K mono-PEG leptin	10	7	2+ to 3+	None
	3	Fleximer1-leptin	10	7	None	None
	4	Fleximer2-leptin	10	7	None	None
30	5	Fleximer2-leptin	1	7	None	None
	6	Fleximer2-leptin	10	1	None	None
	7	Fc-leptin	10	1	None	None

The Table 3 data demonstrates that the Fleximer1-leptin and Fleximer2-leptin conjugates did not induce vacuoles in renal epithelium or splenic macrophages of the mice, whereas the 20K mono-PEG leptin was moderately
5 vacuologenic.

EXAMPLE 5

This example describes the preparation of Fleximer1-IL-1ra, Fleximer2-IL-1ra, FleximerG20-IL-1ra,
10 and FleximerG50-IL-1ra conjugates. Recombinant methionyl human IL-1ra, prepared as described in the Materials and Methods section below, was used for the conjugations.

15 Synthesis of Fleximer1-IL-1ra Conjugates

Preparation 1: 848.0 mg (49.1 μ mol) of IL-1ra (3.685 mL of a 229.9 mg/mL solution) was added to a solution of 442.0 mg (24.6 μ mol) of Fleximer1 in 165 mL of maleimide buffer (20 mM phosphate pH 6.5 containing 5
20 mM EDTA) and stirred in the cold room for 3 days.

Purification 1: A 25 mL aliquot of the reaction mixture was filtered (0.45 μ m CA), then dialyzed overnight in two Pierce Slide-A-Lyzer 3.5 cassettes with 2L of 20 mM NaOAc pH 5.4. The dialyzate
25 was loaded onto a HiLoad 26/10 SP Sepharose HP FPLC column in 20 mM NaOAc pH 5.4 and eluted with a 0.5 M NaCl gradient. Fractions 40-67 were pooled: 336 mL x 0.05155 mg/mL = 17.3 mg protein.

Purification 2: A 40 mL aliquot of the
30 reaction mixture was filtered (0.45 μ m CA), then injected onto the FPLC as described in Purification 1

A-822

without prior dialysis. Fractions 18-50 were pooled:
 $396 \text{ mL} \times 0.07521 \text{ mg/mL} = 29.8 \text{ mg protein.}$

Purification 3: A 40 mL aliquot of the reaction mixture was filtered ($0.45 \mu\text{m}$ CA), then
5 dialyzed as per Purification 1. The dialyzate was combined with material from a prior preparation (8.1 mg protein) then injected onto the FPLC as described in Purification 1. Fractions 20-50 were pooled: $372 \text{ mL} \times 0.08622 \text{ mg/mL} = 32.1 \text{ mg protein.}$

10 Purification 4: A 40 mL aliquot of the reaction mixture was processed as per Purification 2. Fractions 10-49 were pooled: $480 \text{ mL} \times 0.05239 \text{ mg/mL} = 25.1 \text{ mg protein.}$

15 Purification 5: A 22 mL aliquot of the reaction mixture plus 5 mL (25.7 mg protein) from a prior preparation was processed as per Purification 2. Fractions 13-49 were pooled: $444 \text{ mL} \times 0.03355 \text{ mg/mL} = 14.9 \text{ mg protein.}$

20 The pools from Purifications 1-5 were combined (2028 mL, 109.2 mg protein) and concentrated in a 400 mL stirred cell with a YM-3 membrane (pre-sterilized with 70% ethanol) to ~50 mL. This material was diafiltered with D-PBS then concentrated to 14.0 mL which was filtered with a Millipore Steriflip Filter
25 Unit ($0.22 \mu\text{m}$) ($7.73 \text{ mg/mL} = 108.3 \text{ mg protein.}$ Endotoxin testing (Pyrotell, Associates of Cape Cod, catalog No. GS006) showed >1 and $<5 \text{ EU/mL}$. This solution was submitted for *in vivo* testing.

30 Synthesis of Fleximer2-IL-1ra Conjugates

Preparation 1: 43.1 mg ($2.50 \mu\text{mol}$) of IL-1ra ($187.4 \mu\text{L}$ of a 229.9 mg/mL solution) was diluted with 10 mL of

maleimide buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA) and then added to a solution of 137.5 mg (1.25 μ mol) Fleximer2 in 10 mL of maleimide buffer and stirred in the cold room for 5 days.

5 The reaction mixture was diluted with 20 mL of D-PBS and filtered through a coarse sintered glass funnel. The filtrate was placed in a 200 mL Amicon stirred cell with a YM-100 membrane and diafiltered vs. D-PBS. The retentate was 38 mL at 0.881 mg/mL = 33.5
10 mg protein.

Preparation 2: 129.3 mg (7.50 μ mol) of IL-1ra (562 μ L of a 229.9 mg/mL solution) was added to a solution of 412.5 mg (3.75 μ mol) of Fleximer2 in 60 mL of maleimide buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA)
15 and stirred in the cold room for 2 days.

 The reaction mixture was diluted with 60 mL of D-PBS and filtered through a coarse sintered glass funnel. The filtrate was placed in a 200 mL Amicon stirred cell with a YM-100 membrane and diafiltered vs.
20 D-PBS. A total of 1100 mL of diafiltrate was collected. The retentate, 105 mL at 1.136 mg/mL = 106.1 mg protein, was combined with the product from Preparation 1 and concentrated to 31 mL. This solution was diluted to 350 mL with D-PBS and filtered (0.45 μ m
25 CA; very slow). The filtrate contains 64.4 mg of protein (350 mL at 0.1839 mg/mL; 49.0% recovery).

Preparation 3: 129.3 mg (7.50 μ mol) of IL-1ra (562 μ L of a 229.9 mg/mL solution) was added to a solution of 412.5 mg (3.75 μ mol) Fleximer2 in 60 mL of maleimide
30 buffer (20 mM phosphate pH 6.5 containing 5 mM EDTA) and stirred in the cold room for 3 days.

- The reaction mixture was diluted with 60 mL of D-PBS and filtered through a coarse sintered glass funnel. The filtrate was placed in a 200 mL Amicon stirred cell with a YM-100 membrane and diafiltered vs. D-PBS. A total of 1725 mL of diafiltrate was collected. The retentate was diluted to 500 mL with D-PBS and filtered (0.45 μ m CA; very slow). The filtered material contained 58.7 mg of protein (500 mL at 0.1173 mg/mL).
- The product from Preparation 3 was combined with the Preparation 1/2 product mixture in a 400 mL stirred cell (pre-sterilized with 70% ethanol; YM-10 membrane) and concentrated to 17.0 mL (6.16 mg/mL = 104.7 mg protein). Endotoxin testing (Pyrotell, Associates of Cape Cod, catalog No. GS006) showed ≥ 10 and < 100 EU/mL. This solution was submitted for *in vivo* testing.

Synthesis of FleximerG20-IL-1ra Conjugates

- Preparation 1: 103.0 mg (5.15 μ mol) of FleximerG20 was dissolved in 1.03 mL of 100 mM phosphate buffer pH 6.9 and treated with NaIO₄ (42.7 μ L of a 50.0 mg/mL solution in water; 10.0 μ mol) at room temperature in the dark for 30 minutes. The reaction mixture was diluted with 1.82 mL of 100 mM phosphate buffer pH 5.0 and applied to a Bio-Rad PD-6 column in the same buffer. The eluant (~4 mL) was cooled to 4°C, and then mixed with IL-1ra (1.88 mL of a 229.9 mg/mL solution; 432. mg, 25.0 μ mol) and sodium cyanoborohydride (318 μ L of a 1.0 M solution in water; 318 μ mol). The reaction mixture was stirred in the cold room for 26 days while a white suspension slowly formed.

The white suspension was diluted with 6 mL of 20 mM acetate buffer pH 5.4, stirred for 1 hour in the cold and filtered (0.45 μ m CA). The filtrate was loaded onto a HiLoad 26/10 SP Sepharose HP FPLC column in 20 mM NaOAc pH 5.4 and eluted with a 0.5 M NaCl gradient. Fractions 5-8 were pooled: 48 mL at 0.642 mg/mL = 30.8 mg protein.

Preparation 2: 309.0 mg (15.4 μ mol) of FleximerG20 was dissolved in 3.09 mL of 100 mM phosphate buffer pH 6.9 and treated with NaIO₄ (128.1 μ L of a 50.0 mg/mL solution in water; 30.0 μ mol) at room temperature in the dark for 30 minutes. The reaction mixture was diluted with 5.46 mL of 100 mM phosphate buffer pH 5.0 and 3 X 3 mL applied to three Bio-Rad PD-6 columns in the same buffer. The combined eluants (~12 mL) were cooled to 4°C, and then mixed with IL-1ra (5.64 mL of a 229.9 mg/mL solution; 1296. mg, 75.0 μ mol) and sodium cyanoborohydride (954 μ L of a 1.0 M solution in water; 954 μ mol). The reaction mixture was stirred in the cold room for 34 days while a white suspension slowly formed.

The white suspension was diluted with 18 mL of 20 mM acetate buffer pH 5.4, stirred for 2 hours in the cold and filtered (0.45 μ m CA + pre-filter). The filtrate was loaded onto a HiLoad 26/10 SP Sepharose HP FPLC column in 20 mM NaOAc pH 5.4 and eluted with a 0.5 M NaCl gradient. Fractions 5-8 were pooled: 48 mL at 2.63 mg/mL = 126.5 mg protein.

The pooled conjugate fractions from Preparations 1 and 2 were combined and concentrated in two Amicon Centriprep YM-10's, then diluted and concentrated twice using D-PBS leaving 14.2 mL at 9.640 mg/mL = 136.9 mg protein. GPC analysis showed 0.49%

A-822

free IL-1ra present; endotoxin testing (Pyrotell, Associates of Cape Cod, catalog No. GS006) showed <10 EU/mL. This solution was submitted for *in vivo* testing.

5

Synthesis of FleximerG50 aldehyde-IL-1ra Conjugates

1.0656 g (21.3 μ mol) of FleximerG50 was dissolved in 7.4 mL of 100 mM phosphate buffer pH 6.9, sodium periodate (0.0085 g, 40.0 μ mol) and stirred at
10 room temperature in the dark for an hour. The reaction mixture was diluted with 3.44 mL of 100 mM phosphate buffer, pH 5.0. The reaction mixture was divided into four portions and each portion loaded onto a Bio-Rad PD-6 column which was equilibrated with 5 mL of 100 mM
15 phosphate buffer, pH 5.0. Each column was eluted with ~4 mL of the same buffer, and the eluants combined and cooled to 4°C.

IL-1ra (1.7g, 98 μ mol) was added to the FleximerG50 aldehyde solution and the solution was
20 treated with sodium cyanoborohydride (final concentration of 15 mM). The reaction was stirred at 4°C for 37 days and followed by GPC. The polymer conjugate was purified by FPLC. The reaction mixture was diluted with 20 mM sodium acetate pH 5.4 to 150 ml
25 and filtered through a 0.5 μ m membrane. The filtrate was loaded onto a HiLoad 26/10 SP Sepharose HP FPLC column in 20 mM NaOAc pH 5.4 and eluted with a 1.0 M NaCl gradient. Fractions were assayed by SDS-PAGE (4-20% Tri-Gly; visualized with Coomassie Blue) and
30 fractions 30-39 were pooled: 72 mL at 2.2 mg/mL = 158 mg protein.

EXAMPLE 6

The *in vivo* efficacy of the Fleximer1-IL-1ra conjugate, Fleximer2-IL-1ra conjugate, FleximerG20-IL-1ra conjugate, and FleximerG50-IL-1ra conjugate was tested in a rat arthritis model by monitoring paw swelling relative to a HSA and collagen control. Fc-IL-1ra preparations and HSA-IL-1ra preparations were also evaluated.

Study 1. Collagen-induced arthritic (CIA) rats (Lewis Rats; 1 mg collagen/IFA emulsion) were treated with a single subcutaneous injection of 30 mg/kg Fc-IL-1ra, Fleximer1-IL-1ra, Fleximer2-IL-1ra or HSA-IL-1ra on arthritis day 0. The extent of inflammation (paw swelling (mm)) was calculated as increase in ankle joint width compared to arthritis day 0. Kruskal-Wallis ANOVA and Mann-Whitney U test was used to evaluate differences between any two groups. A p value of less than 0.05 was considered significant. Paw swelling was measured for 7 days post onset.

As depicted in Table 4 below, the Fleximer2-IL-1ra preparation and Fc-IL-1ra preparation were most effective in minimizing the extent of inflammation in the CIA rats.

Table 4

		Paw Swelling (mm)		
<u>Sample</u>		<u>Day 2</u>	<u>Day 4</u>	<u>Day 6</u>
Normal		0	0	0
Collagen Control		.80 mm	1.1 mm	1.45 mm
HSA Control		.40 mm	.86 mm	1.25 mm
Fc-IL-1ra		.10 mm	.35 mm	.85 mm
Fleximer1-IL-1ra		.35 mm	.91 mm	1.27 mm
Fleximer2-IL-1ra		.23 mm	.63 mm	.88 mm

HSA-IL-1ra .41 mm .90 mm 1.27 mm

Study 2. Collagen-induced arthritic (CIA)
 5 rats (Lewis Rats; 1 mg collagen/IFA emulsion) were
 treated with a single subcutaneous injection of 30
 mg/kg, 10 mg/kg, or 3 mg/kg Fc-IL-1ra or Fleximer2-IL-
 1ra on arthritis day 0. The extent of inflammation
 (paw swelling (mm)) was calculated as increase in ankle
 10 joint width compared to arthritis day 0. Paw swelling
 was measured for 7 days post onset.

As depicted in Table 5 below, the Fleximer2-
 IL-1ra preparation and Fc-IL-1ra preparation were both
 effective in minimizing the extent of inflammation in
 15 the CIA rats, with the Fc-IL-1ra preparation at 30
 mg/kg being most effective.

Table 5

		Paw Swelling (mm)		
<u>Sample</u>		<u>Day 2</u>	<u>Day 4</u>	<u>Day 6</u>
20	Normal	0	0	0
	Collagen Control	.90 mm	1.6 mm	2.1 mm
	PBS Control	.90 mm	1.5 mm	2.1 mm
	Fc-IL-1ra (30mg)	.30 mm	.45 mm	.60 mm
	Fc-IL-1ra (10mg)	.62 mm	1.0 mm	1.2 mm
25	Fc-IL-1ra (3mg)	.60 mm	1.15 mm	1.6 mm
	Flex2-IL-1ra (30mg)	.65 mm	1.1 mm	1.6 mm
	Flex2-IL-1ra (10mg)	.60 mm	1.1 mm	1.4 mm
	Flex2-IL-1ra (3mg)	.70 mm	.90 mm	2.0 mm

30 Study 3. Collagen-induced arthritic (CIA)
 rats (Lewis Rats; 1 mg collagen/IFA emulsion) were
 treated with a single subcutaneous injection of 30
 mg/kg Fc-IL-1ra or FleximerG20-IL-1ra on arthritis day
 0. The extent of inflammation (paw swelling (mm)) was

A-822

calculated as increase in ankle joint width compared to arthritis day 0. Paw swelling was measured for 7 days post onset.

As depicted in Table 6 below, the FleximerG20-IL-1ra preparation was effective in minimizing the extent of inflammation in the CIA rats.

Table 6

		Paw Swelling (mm)		
<u>Sample</u>		<u>Day 2</u>	<u>Day 4</u>	<u>Day 6</u>
10	Normal	0	0	0
	Collagen Control	.80 mm	1.7 mm	2.1 mm
	PBS Control	.70 mm	1.7 mm	2.2 mm
	Fc-IL-1ra	.20 mm	.70 mm	1.3 mm
15	FleximerG20-IL-1ra	.45 mm	1.1 mm	1.8 mm

Study 4. Collagen-induced arthritic (CIA) rats (Lewis Rats; 1 mg collagen/IFA emulsion) were treated with a single subcutaneous injection of 30 mg/kg Fc-IL-1ra or FleximerG50-IL-1ra on arthritis day 0. The extent of inflammation (paw swelling (mm)) was calculated as increase in ankle joint width compared to arthritis day 0. Paw swelling was measured for 7 days post onset.

As depicted in Table 7 below, the FleximerG50-IL-1ra preparations was effective in minimizing the extent of inflammation in the CIA rats.

Table 7

		Paw Swelling (mm)		
<u>Sample</u>		<u>Day 2</u>	<u>Day 4</u>	<u>Day 6</u>
30	Normal	0	0	0
	Collagen Control	.60 mm	1.3 mm	1.75 mm
	PBS Control	.40 mm	1.2 mm	1.5 mm
	Fc-IL-1ra	.15 mm	.40 mm	1.1 mm

EXAMPLE 7

PHF was prepared as described above, using
5 dextran B-512 with molecular weight of 188 kDa. PHF
(100 mg), succinic anhydride (7.5 mg, 0.075 mmol) and
DMAP (1.2 mg, 0.01 mmol) were dissolved in 5 ml of
anhydrous pyridine. After 18 hours of incubation at
40°C, pyridine was removed in vacuum, the residue was
10 suspended in deionized water, and the pH was adjusted
to 7.0 by addition of 1 N NaOH. The product,
succinylated PHF, was purified on Sephadex G-25 with
deionized water as an eluent, and recovered via
lyophilization. The succinic acid content, as
15 determined by potentiometric titration, was 11.3%. The
¹H NMR spectrum of the polymer (D₂O) contained signals
of characteristic methylene protons of succinic acid
ester at δ 2.62 (t) and δ 2.46 (t).

20 PHF-SA-trypsin conjugates: The solution of PHF-SA with
Mn 176 kDa (100 mg) in 2.0 mL of deionized water was
combined with 3.0 ml of 5.0 mg/ml trypsin solution in
0.1M phosphate buffer pH 7.4. EDC (20 mg) was added to
the reaction mixture in 500 uL of cold (0-5 °C)
25 deionized water immediately after dissolution. Trypsin
conversion after 3 hours of incubation according HPLC
(UV at 280 nm) was 97%. The reaction mixture was
purified of low molecular weight products and
concentrated to approximately 10 mg/ml on PM-30
30 ultrafiltration membrane using 0.05 M PBS pH 7.0. The
conjugate was separated of residual not bound trypsin
by Superose-6 column (Pharmacia) with 0.5M PBS pH 7.0
as a running buffer. The resulting conjugation product
was stored frozen at -40°C. SEC analysis of this

conjugate has shown Mn 245 kDa, PI 1.8, and peak polymer MW 260 kDa. Trypsin conjugate content estimated by HPLC and spectroscopically at 280 nm was 10.7% wt.

5 For animal studies, protein conjugates were labeled with [^{111}In] after modification of the trypsin portion of conjugates with DTPA. EDC mediated coupling was carried out in aqueous solution at DTPA/EDC/Trypsin lysine residue ratio 500:50:1 at pH 7.5. The product
10 was purified by gel filtration. DTPA to protein molar ratio determined by Cu(II) colorimetric assay at 775 nm was approximately 1:4.

 Labeling was performed by transchelation from [^{111}In] citrate. The labeling solution was prepared by
15 mixing [^{111}In]InCl solution in 0.05 M HCl with 20-fold volume excess of 0.5 M sodium citrate, pH=5.6. The resultant [^{111}In] citrate solution was added to unbuffered solution of the DTPA-derivatized conjugate, 0.2 [^{111}In] per 1 mg dry substance. The labeled
20 conjugate was separated by gel filtration on Sephadex G-25, with simultaneous buffer replacement to sterile isotonic saline. Labeling efficacy after transchelation estimated by HPLC equipped with gamma detector on average exceeded 90%, and radiochemical
25 purity after desalting was >99%.

 Adult male CD1 mice (28 g to 34 g, from Charles River Laboratories, Wilmington, MA) were injected IV via the tail vain with 150 μL of ^{111}In -labeled polymer solution (containing approximately
30 10 μCi per injection). Mice were sacrificed at 0.25, 0.5, 1, 2, 4, and 8 hours (n=2 per point), blood samples were taken and specified organs (hart, lungs, liver, spleen, kidneys, adrenal glands, stomach, GI, testes, muscle, bone, brain and tail) were harvested

and analyzed on gamma counter. The amount of radioactivity was expressed as a percentage of the injected dose per gram tissue.

- Unmodified radiolabeled trypsin preparation
- 5 (control) showed clearance of 80% of activity from blood within 15 minutes after administration (*i.e.*, initial blood half life ca. 7 min), followed by an apparently monoexponential clearance with 4 ± 0.8 hour half-life, where the first (main) phase is consistent
- 10 with renal clearance and extravasation into interstitial space in various tissues, and the second phase can be related to redistribution back from the tissues and prolong circulation of trypsin complexes with proteins of plasma.
- 15 PHF-Trypsin conjugate showed a bi-phasic blood clearance with approximately 40% of activity cleared within 1 hour, the rest (main fraction) remained in circulation with a half-life time of 8 hours, which is consistent with extravasation of the
- 20 smaller fraction of the unfractionated conjugate, and the second phase is consistent with circulation of the main fraction.

Materials and Methods

- 25 The water-soluble polymers contemplated for use are the biodegradable, biocompatible polyacetals described in U.S. Patent Nos. 5,811,510, 5,863,990, and 5,958,398. A preferred polymer is poly-(hydroxymethylene hydroxymethylformal).
- 30 Recombinant methionyl human leptin (rmetHu-leptin) was prepared as described in in PCT International Publication Numbers WO 96/05309 and WO 00/21574, each of which is herein incorporated by

reference in its entirety. The leptin moieties used herein may be made in prokaryotic or in eukaryotic cells, although, for the leptin moieties used in the working examples below, bacteria is preferred for ease
5 in commercial manufacture. One may further use leptin made in human cells, such as that made by controlling a native or introduced regulatory element which affects the regulation of an endogenous gene encoding the desired protein.

10 Recombinant methionyl human Il-1ra was prepared as described in e.g., U.S. Patent No. 5,075,222. One may further use Il-1ra made in human cells, such as that made by controlling a native or introduced regulatory element which affects the
15 regulation of an endogenous gene encoding the desired protein.